Detalhe da pesquisa
1.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Blood
; 143(5): 417-421, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879077
2.
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
Blood
; 143(20): 2059-2072, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437498
3.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441846
4.
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
Cancer
; 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38804723
5.
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage.
Cancer
; 2024 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38896064
6.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591430
7.
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
Cancer
; 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38809547
8.
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
; 204(3): 898-909, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946611
9.
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
Br J Haematol
; 204(6): 2259-2263, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603594
10.
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
Br J Haematol
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38724457
11.
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Blood
; 140(1): 58-72, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390143
12.
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Blood
; 139(6): 907-921, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34601571
13.
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Blood
; 140(16): 1753-1763, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512188
14.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695144
15.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361282
16.
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Am J Hematol
; 99(5): 836-843, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400519
17.
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Cancer
; 129(4): 580-589, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36448227
18.
Association between bariatric surgery and outcomes in chronic myeloid leukemia.
Cancer
; 129(12): 1866-1872, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882573
19.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
20.
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Cancer
; 129(12): 1856-1865, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892949